

REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Crosswalk-a

Main Information	
Primary registry identifying number	Protocol number
LBCTR2024045330	BO42452
MOH registration number	
Study registered at the country of origin	Study registered at the country of origin: Specify
Yes	
Type of registration	Type of registration: Justify
Prospective	N/A
Date of registration in national regulatory agency 15/01/2021	
Primary sponsor	Primary sponsor: Country of origin
F. Hoffmann-La Roche Ltd	Switzerland
Date of registration in primary registry	Date of registration in national regulatory agency
14/10/2024	15/01/2021
Public title	Acronym
Crosswalk-a	Crosswalk-a
Scientific title	Acronym
A Phase IB Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso- Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)	Crosswalk-a
Brief summary of the study: English	
Background on Sickle Cell Disease: Sickle cell disease (SCD) is an autosomal recessive genetic disorder caused by the inheritance of a point mutation at position 6 in the β -globin gene, replacing a glutamic acid with a valine (β S). It affects millions of patients with an estimated incidence of 300,000- 400,000 affected neonates annually.	
The polymerized HbS distorts the Red Blood Cells into a sickled shape with abnormal rheology. The increased rigidity and decreased deformability of sickled RBCs contribute to microvascular occlusions and the hallmark presentation of acute painful vaso-occlusive episodes in patients with Sickle Cell Disease. Vaso-occlusive episodes are marked by ischemia and reperfusion injury, which can affect any organ system in the body.	
Acute painful episodes can range, from being managed at home to requiring hospital admission, and can be complicated by additional acute sickle cell manifestations including acute chest syndrome and hepatic and/or splenic sequestration. Sickled Red blood Cells have a significantly shorter lifespan as a result of chronic intravascular and extravascular hemolysis causing chronic anemia. The chronic hemolysis causes chronic endothelial activation leading to vascular dysfunction that can manifest clinically as vascular stiffness, pulmonary hypertension, diastolic heart failure, and renal damage.	

 \sim



The release of intracellular contents also results in chronic sterile inflammation with activation of leukocytes, platelets, endothelial cells, and generation of reactive oxygen species. In addition, Sickle Cell Disease May also result in moderate to severe chronic anemia, immune dysfunction, chronic pain, and progressive end-organ damage in the lungs, heart, kidney, and central nervous system

These acute and chronic complications of Sickle Cell Disease contribute to the significant morbidity and mortality in this patient population.

The management/ treatment of Sickle Cell disease is complex and depends on the patient's age, comorbidities, and disease phenotype. In patients diagnosed in the neonatal period, anticipatory guidance and supportive care with antibiotic prophylaxis and vaccinations has improved childhood outcomes.

Globally, treatment of Sickle Cell Disease is limited to hydroxyurea, which has disease-modifying efficacy, blood transfusion, and other supportive care for acute and chronic complications. Hematopoietic stem cell transplantation (HSCT) is the only available curative intervention; however, it is limited by donor availability and procedure-associated toxicity.

Morbidity and mortality data highlight the unmet need in Sickle Cell Disease. Although medical advances have significantly improved life expectancy in patients with HbSS or HbS β 0 to a median of more than 60 years, especially in high-resource countries, life expectancy remains about 30 years less than in the general population and morbidity burden of disease remains high.

Complement Inhibition C5 on sickle cell disease

Taken together, the available data from patients with Sickle Cell Disease, and in vitro and in vivo nonclinical models indicate that complement is activated in patients with Sickle Cell Disease And suggest a role in its pathophysiology in multiple domains. Complement activation is detected in patients at steady state in Sickle Cell Disease And in association with acute vaso-occlusive episodes . In vitro and in vivo models of complement inhibition suggest multiple potential downstream effects of C5 inhibition in patients with Sickle Cell Disease That include prevention of endothelial activation by free heme, reduction in rate of hemolysis, reduction in vaso-occlusion, improvement in chronic inflammation, and reduction in end-organ damage.Published evidence supports exploratory trials of complement inhibition in patients with Sickle Cell Disease, which may address the unmet medical need in this disease, employing a mechanism that does not overlap with current therapies.

Crovalimab effect:

Crovalimab induces rapid and complete inhibition of the terminal complement pathway by targeting C5, making it a suitable candidate for exploration of the role of targeting complement in treatment for Sickle Cell Disease .

BO42452 Study Objective

BO42452 will evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of crovalimab compared with placebo for the management of acute uncomplicated Vasoocculsive episodes in patients with sickle cell disease . (Kindly check the objectives and endpoint in protocol section 2 page 34). This randomized, multicenter, placebo-controlled, double-blinded Phase lb study is designed to evaluate the safety (primary study objective), pharmacokinetics, pharmacodynamics, and efficacy of crovalimab compared with placebo for the management of an acute uncomplicated vaso-occulsive episodes in adult and adolescent patients with sickle cell disease.

BO42452 Design

This study will enroll approximately 30 patients (at approximately 10 -15 sites globally), aged 12-55 years old and ≥40 kg, with sickle cell disease genotype of HbSS or HbS β 0, presenting to the ER/ED or acute medical facility with an acute uncomplicated vaso-occulsive episodes. Patients who present with acute complications such as



acute chest syndrome, priapism, hepatic or splenic sequestration etc., or present with pain atypical of or unrelated to an acute uncomplicated vaso-occulsive episodes will be excluded at screening. Complications of the vaso-occulsive episodes that develop after study treatment administration and during hospitalization will be documented. Patients who develop complications after screening, but before study treatment administration, may no longer be eligible.

A 2-step process for screening procedures is encouraged to preliminarily identity and consent patients for the study prior to vaso occlusive episodes presentation:

Screening Visit #1 (initial screening) is conducted at an outpatient visit (i.e., when the patient is not experiencing a vaso occlusive episode), where the main Informed Consent Form is signed and preliminary eligibility is assessed. During this visit, preliminary screening assessments can be conducted, and a steady state sickle cell disease exploratory biomarker sample will be collected (only after consent is received), No additional assessments are required until Screening Visit #2.

Eligibility at Screening Visit #1 does not guarantee eligibility at Screening Visit #2.

Screening Visit #2 (vaso-occlusive episodes crisis screen) is then conducted when the patient presents with a vaso-occulsive episodes to the ER/ED or acute medical facility. The patient consent from Screening Visit #1 must be confirmed prior to starting study assessments (this confirmation must be documented). Once patient consent is confirmed, all remaining eligibility criteria must be assessed. (Refer to study design for more info in protocol page 37)

The patients enrolled in the study will be randomized 2:1 in this study.

Crovalimab dosing

A single IV dose of crovalimab at 1000 mg (\geq 40 to \leq 100 kg) or 1500 mg (\geq 100 kg) will be administered in this study. The goal of the single dose treatment is to achieve rapid and complete C5 activity inhibition for a short term.

Data from Studies BP39144 and YO42311 in healthy subjects and PNH patients indicate that crovalimab serum concentration above 100 g/mL achieves complete complement inhibition. In the therapeutic use of C5 inhibitors, regardless of indication (e.g., PNH, aHUS, neuromyelitis optica, myasthenia gravis), there has been minimal evidence to date to support that less-than-complete complement inhibition is an acceptable therapeutic approach.

End of the study

The end of this study is defined as the date when the last patient's last visit occurs, or

the date at which the last data point is received from the last patient on study, whichever occurs later. The end of the study is expected to occur approximately 322 days or approximately 10.5 months after the last patient is enrolled.

Brief summary of the study: Arabic

خلفية عن مرض الخلايا المنجلية

مما يؤدي ،β-globin في جين6هو اضطراب وراثي جسمي متنحي ناجم عن وراثة طفرة نقطية في الموضع (SCD) مرض الخلايا المنجلية إلى300.000إنه يؤثر على ملايين المرضى الذين يقدر عددهم بحوالي .(βS) إلى استبدال حمض الجلوتاميك بحمض أميني أساسي طفل حديث الولادة سنويًا 400.000

المبلمر بتشويه خلايا الدم الحمراء إلى شكل منجل مع ريولوجيا غير طبيعية. تساهم الصلابة المتزايدة وانخفاض تشوه كرات الدم HbS يقوم الحمراء المنجلية في انسداد الأوعية الدموية الدقيقة والعرض المميز لنوبات انسداد الأوعية الدموية الحادة المؤلمة لدى المرضى الذين يعانون من مرض فقر الدم المنجلي. تتميز نوبات انسداد الأوعية الدموية بنقص التروية وإصابة إعادة ضخ الدم، والتي يمكن أن تؤثر على أي جهاز عضوي في الجسم

يمكن أن تتراوح النوبات المؤلمة الحادة، من العلاج في المنزل إلى الحاجة إلى دخول المستشفى، ويمكن أن تكون معقدة بسبب مظاهر الخلايا المنجلية الحادة الإضافية بما في ذلك متلازمة الصدر الحادة و عزل الكبد و/أو الطحال. تتمتع خلايا الدم الحمراء المنجلية بعمر أقصر بكثير نتيجة لاتحلال الدم المزمن داخل الأو عية وخارج الأو عية الدموية الذي يسبب فقر الدم المزمن. يتسبب انحلال لدم المزمن في تتشيط بطانة الأو عية الدموية المزمن مما يؤدي إلى خلل في الأو عية الدموية الذي يسبب فقر الدم المزمن. يتسبب انحلال لدم المزمن في تتشيط بطانة الأو عية الدموية المزمن مما يؤدي إلى خلل في الأو عية الدموية يمكن أن يظهر سريريًا على شكل تصلب الأو عية الدموية وارتفاع ضغط الدم الرئوي وفشل القلب الانبساطي وتلف الكلى. يؤدي إطلاق المحتويات داخل الخلايا أيضاً إلى التهاب مزمن معقم مع تنشيط كريات الدم وفشل القلب الانبساطي وتوليد أنواع الأكسجين التفاعلية. بالإصافة إلى ذلك، قد يؤدي مرض فقر الدم المنجلي ألى فقر ما الدموية والخلايا البطانية وتوليد أنواع الأكسجين التفاعلية. بالإصافة إلى ذلك، قد يؤدي مرض فقر الدم المنجلي ألى فقر معقر معاتر م الدموية والخلايا المندي وتوليد أنواع الأكسجين التفاعلية. بالإصافة إلى ذلك، قد يؤدي مرض فقر الدم المنجلي ألى فقر ما مرض مع الدموية والخلايا البطانية وتوليد أنواع الأكسجين التفاعلية. بالإصافة إلى ذلك، قد يؤدي مرض فقر الدم المنجلي ألى فقر مر من فقر الدم المنجلي ألى والمواني الى شديد، وخلل في المناعة، وألم مزمن، وتلف تدريجي للأعضاء النهائية في الرنتين والقلب والكلى والجهاز العصبي المركزي REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

بتساهم هذه المضاعفات الحادة والمزمنة لمرض فقر الدم المنجلي في ارتفاع معدلات الإصابة بالمرض والوفيات بين هذه الفئة من المرضى

تعد إدارة/علاج مرض الخلايا المرضية أمرًا معقدًا ويعتمد على عمر المريض والأمراض المصاحبة والنمط الظاهري للمرض. في المرضى الذين تم تشخيصهم في فترة حديثي الولادة، أدى التوجيه الاستباقي والرعاية الداعمة بالعلاج الوقائي بالمضادات الحيوية واللقاحات إلى تحسين نتائج الطفولة

على الصعيد العالمي، يقتصر علاج مرض فقر الدم المنجلي على الهيدروكسي يوريا، الذي يتمتع بفعالية في تعديل المرض، ونقل الدم، وغير ها هو التدخل العلاجي الوحيد المتاح؛ ومع (HSCT) من الرعاية الداعمة للمضاعفات الحادة والمزمنة. يعتبر زرع الخلايا الجذعية المكونة للدم ذلك، فهو محدود بتوافر الجهات المانحة والسمية المرتبطة بالإجراءات

تسلط بيانات معدلات المراضة والوفيات الضوء على الاحتياجات غير الملباة في مُرض فقر الدم المنجلي. على الرغم من أن التقدم الطبي قد أدى عامًا، خاصة في60إلى متوسط يزيد عن HbSβ0 أو HbSS إلى تحسين كبير في متوسط العمر المتوقع لدى المرضى الذين يعانون من عامًا من عامة السكان ويظل عبء المراضة الناتج عن المرض30البلدان ذات الموارد العالية، إلا أن متوسط العمر المتوقع لا يز ال أقل بنحو .

لمرض فقر الدم المنجلي - C5 - تثبيط المكمل

مجتمعة، تشير البيانات المتاحة من المرضى الذين يعانون من مرض فقر الدم المنجلي، وفي النماذج غير السريرية في المُختبر وفي الجسم الحي إلى أن المكمل يتم تنشيطه في المرضى الذين يعانون من مرض فقر الدم المنجلي، وتشير إلى دور في الفسيولوجيا المرضية في مجالات متعددة تم الكشف عن التنشيط التكميلي في المرضى الذين يعانون من حالة مستقرة في مرض الخلايا المنجلية وبالتزامن مع نوبات انسداد الأو عية الدموية في المرضى الذين يعانون من مرض 50 الحادة. تشير نماذج التثبيط التكميلي في المختبر وفي الجسم الحي إلى تأثيرات متعددة محتملة لتثبيط الخلايا المنجلية، والتي تشمل الوقاية من تنشيط بطانة الأو عية الدموية عن طريق الهيم الحر، وانخفاض معدل الحرارات متعددة محتملة لتثبيط الأو عية الدموية، والتي تشمل الوقاية من تنشيط بطانة الأو عية الدموية عن طريق الهيم الحر، وانخفاض معدل الحمال الدم، وانخفاض انسداد الأو عية الدموية، والتي تشمل الوقاية من تنشيط بطانة الأو عية الدموية عن طريق الهيم الحر، وانخفاض معدل الحمال الدم، وانخفاض انسداد الخلايا المنجلية، والتي تشمل الوقاية من تنشيط بطانة الأو عية الدموية عن طريق الهيم الحر، وانخفاض معدل الدم، وانخاض انسداد الو عية الدموية، وتعسين الالتهاب المزمن، و تقليل تلف الأعضاء النهائية. تدعم الأدلة المنشورة التبر الم معنوبات الموية التكميلي في الو عية الدموية، وتحسين من مرض 50 المزمن، و تقليل تلف الأعضاء النهائية. تدعم الأدلة المنشورة التجارب الاستكثافية التثبيط التكميلي في المرضي الذين يعانون من مرض فقر الدم المنجلي، والتي قد تلبي الاحتياجات الطبية غير الملباة في هذا المرض، وذلك باستخدام آلية لا تتداخل

تأثير كروفاليماب

مما يجعله مرشحًا مناسبًا لاستكشاف دور مكمل ،C5 يحث كروفاليماب على تثبيط سريع وكامل للمسار المكمل الطرفي من خلال أستهداف الاستهداف في علاج مرض فقر الدم المنجلي

BO42452 هدف الدر اسة

بتقييم السلامة والحركية الدوائية والديناميكية الدوائية وفعالية كروفاليماب مقارنة مع الدواء الوهمي لإدارة نوبات انسداد BO42452 ستقوم الأوعية الدموية الحادة غير المعقدة في المرضى الذين يعانون من مرض فقر الدم المنجلي. (يرجى التحقق من الأهداف ونقطة النهاية في قسم .(34)، الصفحة 2البروتوكول

تم تصميم هذه الدراسة العشوانية متعددة المراكز والمضبوطة بالعلاج الوهمي ومزدوجة التعمية لتقبيم سلامة (هذه الدراسة الأساسي) والحركية الدوانية والديناميكا الدوانية وفعالية كروفاليماب مقارنة مع الدواء الوهمي لإدارة نوبات انسداد الأرعية الدموية الحادة غير المعقدة في المرضى البالغين والمراهقين الذين يعانون من مرض فقر الدم المنجلي

BO42452 تصميم الدراسة

40 عامًا ووزن ≤52-12 موقعًا على مستوى العالم)، تتراوح أعمار هم بين 15-10 مريضًا (في حوالي 30ستسجل هذه الدراسة ما يقرب من وسيقدمون إلى غرفة الطوارئ/الطوارئ أو إلى منشأة طبية حادة مع HbSβ0 أو HbSβ كجم، مصابين بالنمط الجيني لمرض الخلايا المنجلية ،نوبات انسداد الأوعية الدموية الحادة غير المعقدة سيتم استبعاد المرضى الذين يعانون من مضاعفات حادة مثل متلازمة الصدر الحادة، أو القساح أو عزل الكبد أو الطحال وما إلى ذلك، أو الذين يعانون من ألام غير نمطية أو غير مرتبطة بنوبات انسداد الأوعية الدموية الفصص. سيتم توثيق مضاعفات نوبات انسداد الأوعية الدموية التي يتطور بعد إدارة علاج الدراسة وأثناء العلاج في المستشف. يصابعن من عليم توثيق مضاعفات نوبات انسداد الأوعية الدموية التي تتطور بعد إدارة علاج الدراسة وأثناء العلاج في المستشفي. المرضى الذين معانون من مؤلمن من عليم معانون من مؤلم فير مطيعة أو غير مرتبطة بنوبات انسداد الأوعية الدموية الحادة غير المعقدة، من

(فحص أزمة نوبات انسداد الأوعية الدموية) عندما يعاني المريض من نوبات انسداد الأوعية الدموية إلى 2يتم بعد ذلك إجراء زيارة الفحص رقم قبل بدء تقييمات الدراسة (يجب توثيق هذا1غرفة الطوارى/الطوارئ أو المنشأة الطبية الحادة. يجب تأكيد موافقة المريض من زيارة الفحص رقم التأكيد). بمجرد تأكيد موافقة المريض، يجب تقييم جميع معايير الأهلية المتبقية. (ارجع إلى تصميم الدراسة لمزيد من المعلومات في صفحة (3) التأكيد). في محرد تأكيد موافقة المريض، يجب تقييم جميع معايير الأهلية المتبقية. (ارجع إلى تصميم الدراسة لمزيد من المعلومات في صفحة

. في هذه الدر اسة 2:1سيتم اختيار هم بصورة عشوائية المرضى المسجلين في الدر اسة

جرعات كروفاليماب

كجم) في هذه100 مجم (≥ 1500 كجم) أو 100 للى ≥40 مجم (≤ 1000سيتم إعطاء جرعة واحدة من كروفاليماب في الوريد بمقدار لفترة قصيرة 55 الدراسة. الهدف من العلاج بجرعة واحدة هو تحقيق تثبيط سريع وكامل لنشاط.

إلى أن تركيز مصل كروفاليماب PNH في الأشخاص الأصحاء ومرضى YO42311 في BP39144 تشير البيانات المستمدة من الدراسات PNH، بغض النظر عن الإشارة (على سبيل المثال ،C5 جم / مل يحقق تثبيطا مكملا كاملا. في الاستخدام العلاجي لمثبطات100أعلى من HUS، التهاب النخاع العصبي البصري، الوهن العضلي الوبيل)، كان هناك الحد الأدنى من الأدلة حتى الأن لدعم أن تثبيط المكمل الأقل من ،HUS التهاب النخاع العصبي البصري، الوهن العضلي الوبيل)، كان هناك الحد الأدنى من الأدلة حتى الأن لدعم أن تثبيط المكمل الأقل من ،

نهاية الدراسة


،يتم تعريف نهاية هذه الدراسة على أنها تاريخ آخر زيارة للمريض، أو التاريخ الذي يتم فيه استلام آخر نقطة بيانات من أخر مريض قيد الدراسة . شهرًا من تسجيل آخر مريض10.5 يومًا أو حوالي 322أيهما يحدث لاحقًا. ومن المتوقع أن تتم نهاية الدراسة بعد حوالي

Health conditions/problem studied: Specify

This study is tackling the management of acute uncomplicated vaso occlusive episodes (voe) in patients with sickle cell disease (SCD). This study will enroll approximately 30 patients (at approximately 10-15 sites globally), aged 12-55 years old and \geq 40 kg, with sickle cell disease genotype of HbSS or HbS β 0, presenting to the ER/ED or acute medical facility with an acute uncomplicated vaso-occulsive episodes.

Interventions: Specify

The investigational medicinal products (IMPs) for this study are crovalimab and placebo. Crovalimab will be supplied by the Sponsor as a solution for infusion (IV) from a single-use vial, which contains an extractable volume of 2 mL or 340 mg (nominal) crovalimab. For IV infusion, the crovalimab-vial solution should be diluted in 0.9% (w/v) sodium chloride solution prior to administration.



The placebo will be an aqueous, isotonic, and sterile solution with a similar pH value as the crovalimab drug product. It should be handled, stored, and used in the same manner as crovalimab. The placebo will be filled into the same primary container as the crovalimab drug product

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Approximately 30 patients with SCD presenting to an ER/ED or acute medical facility with an acute uncomplicated VOE and meeting all eligibility criteria will be randomized 2:1 in this study.

Patients in this study will receive a single IV dose of crovalimab or placebo according to a weight-based dosing approach A single IV dose of crovalimab at 1000 mg (≥ 40 to ≤100 kg) or 1500 mg (≥ 100 kg) will be administered in this study.

Study treatment should be administered no longer than 12 hours following the initial evaluation in the ER/ED or acute medical facility for the VOE

Key inclusion and exclusion criteria: Inclusion criteria

MINISTRY OF PUBLIC HEALTH

Key Inclusion Criteria

Screen Visit #1 (Initial Screen)

Signed ICF or Assent Form (as determined by patient's age and individual site and country standards)

•Age >= 12 to <=55 years at time of signing ICF or Assent Form, and VOE presentation

and will be administered by IV infusion with the same volume as weight-based crovalimab.

•Body weight >=40 kg

•Willingness and ability to comply with all study visits and procedures

 Confirmed diagnosis of HbSS (SCD genotype of sickle cell anemia) or HbSβ0 (SCD genotype of sickle cell beta zero thalassemia) •Vaccination against N. meningitidis serotypes A, C, W, and Y prior to initiation of study treatment. Vaccination against serotypes A, C, W, and Y should have been received < 3 years prior to initiation of study treatment, or must be up to date in accordance with the most current local guidelines or SOC, as applicable for patients with complement deficiency and SCD. If vaccination against serotypes A, C, W, and Y is not required per local SOC, the Advisory Committee on Immunization Practices (ACIP) 2020 guidelines should be used. Vaccination against serotype B should be administered in accordance with the most current local guidelines or SOC for patients with complement deficiency and SCD. Vaccination currency against serotypes A, C, W, Y, and B should be maintained throughout the study, including the safety follow-up, per local guidelines

- If vaccination(s) are incomplete or vaccination status is unknown at VOE presentation, or vaccination(s) were received < 2 weeks before treatment administration, appropriate antibiotic prophylaxis per local clinical practice must be initiated. Antibiotic prophylaxis should be continued until the required vaccination(s) are completed and for an additional 2 weeks after completion

•Vaccinations against H. influenzae type B and S. pneumoniae in accordance with most current SCD-specific guidelines or local SOC. If the vaccination(s) are not required per local guidelines, the ACIP guidelines should be used. Vaccination currency should be maintained throughout the study, including the safety follow-up, per local guidelines.

- If vaccination(s) are incomplete or vaccination status is unknown at VOE presentation, or vaccination(s) were received < 2 weeks before treatment administration, appropriate antibiotic prophylaxis per local clinical practice must be initiated. Antibiotic prophylaxis should be continued until the required vaccination(s) are completed and for an additional 2 weeks after completion

•Patients who have been vaccinated (partially or in full) against SARS-CoV-2 with a locally approved vaccine are eligible to be enrolled in the study, as long as it has been 3 days or more after inoculation with the vaccine.

Screen Visit #2 (VOE Presentation Screen)

•All criteria from Screen Visit #1 must be reconfirmed at Screen Visit #2

•Diagnosis of an acute uncomplicated VOE (for definition see Section 2.4.1), that requires admission to a hospital and treatment with parenteral opioid analgesics

•Pain score >= 2 as measured with the NRS on a 0-10 scale

• Ability to receive the single dose of study treatment within 12 hours from initial evaluation in the ER/ED or acute medical facility for the VOE (i.e., first vital signs measurements or first evaluation by a medical professional, whichever is first)

•Adequate hepatic function, including ALT < 3 x ULN and no clinical signs or known laboratory/radiographic evidence that are consistent with cirrhosis

•Adequate renal function, defined as creatinine clearance by the Chronic Kidney Disease Epidemiology Collaboration formula >= 30 mL/min/1.73 m2; patients on dialysis will not be eligible for the study

•Hemoglobin >=5 g/dL

Platelet count >=100,000/µL

•Patients receiving sickle cell therapies (e.g., hydroxyurea, crizanlizumab, L-glutamine, voxelotor, etc.) must be on a stable dose for >= 28 days prior to VOE presentation

•For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception as defined below:

- Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 322 days (approximately 10.5 months) after the dose of study treatment

- A woman is considered to be of childbearing potential if she is post-menarchal, has not reached a post-menopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). The definition of childbearing potential may be adapted for alignment with local guidelines or regulations

- Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices

- The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception. If required per local guidelines or regulations, locally recognized acceptable methods of contraception and

REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

information about the reliability of abstinence will be described in the local ICF. Kindly refer to the inclusion criteria protocol in section 4.1.1 Key inclusion and exclusion criteria: Gender Key inclusion and exclusion criteria: Specify gender Both Key inclusion and exclusion criteria: Age minimum Key inclusion and exclusion criteria: Age maximum 12 55 Key inclusion and exclusion criteria: Exclusion criteria Exclusion Criteria: Screen Visit #1 (Initial Screen) •More than 10 VOEs within the last 12 months prior to presentation, that have required a medical facility visit (e.g., ER/ED, hospital, clinic, infusion center, day hospital, etc.), as determined by medical history or by patient recall History of hematopoietic stem cell transplant •Known or suspected hereditary complement deficiency •History of hypersensitivity, allergic, or anaphylactic reactions to any ingredient contained in crovalimab, including hypersensitivity to human, humanized, or murine monoclonal antibodies or known hypersensitivity to any constituent of the product •Current or previous treatment with a complement inhibitor therapy (e.g., crovalimab, eculizumab, or ravulizumab) Screen Visit #2 (VOE Presentation Screen) •All criteria from Screen Visit #1 must be reconfirmed at Screen Visit #2 pain related to the current VOE ongoing for > 48 hours prior to VOE presentation Major surgery and/or hospitalization for any reason within 30 days prior to VOE presentation •Acute pain related to avascular necrosis (where the presenting pain is limited to the affected joint), hepatic or splenic sequestration, or priapism per investigator assessment •Pain atypical of an acute uncomplicated VOE that is the primary cause for presentation to the ER/ED or acute medical facility (e.g., chronic pain, abdominal pain, headache), or other alternative cause or explanation for pain presentation (e.g., infection, surgical pain) per investigator assessment • Presentation with a critical illness necessitating ICU or critical care admission • Evidence of or suspicion of ACS, defined as: the presence of new segmental radiographic pulmonary infiltrate involving at least one complete lung segment that is consistent with alveolar consolidation but excluding atelectasis, and at least one of the following additional signs or symptoms: chest pain, temperature >= 38.5oC (101.3oF), respiratory symptoms, or exam findings consistent with ACS • Evidence or high suspicion of a severe systemic infection (e.g., osteomyelitis, pneumonia, meningitis, or sepsis) per investigator assessment - Patients with uncomplicated infections (e.g., uncomplicated urinary tract infections, uncomplicated acute otitis media, streptococcal pharyngitis, minor viral infections) may be included as per investigator assessment Presence of fever >= 38oC (100.oF) •Infection requiring hospitalization or treatment with IV antibiotics within the prior 28 days, or oral antibiotics within the prior 14 days of VOE presentation - Patients on prophylactic antibiotics may be included History of N. meningitidis infection within 6 months prior to VOE presentation •Known HIV infection with a documented CD4 count <200 cells/µL within 24 weeks prior to VOE presentation •Transfusion or receipt of blood products within 3 months prior to VOE presentation or as part of BSC regimen for the current VOE, or current participation in a chronic transfusion protocol Immunized with a live attenuated vaccine within 30 days prior to VOE presentation Pregnant or breastfeeding, or intending to become pregnant during the study or within 322 days (approximately 10.5 months) after the study drug administration - Women of childbearing potential must have a documented negative pregnancy test result (urine or serum). If a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test •Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within the prior 28 days of VOE presentation or within five half-lives of that investigational product, whichever was greater •Substance abuse within 12 months prior to VOE presentation, in the investigator's judgment • Concurrent disease, treatment, procedure, surgery, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose any additional risk for the patient, or would, in the opinion of the investigator, preclude the patient's safe participation in and completion of the study Kindly refer to the inclusion criteria in protocol in section 4.1.1 Type of study Interventional Type of intervention Type of intervention: Specify type Pharmaceutical N/A **Trial scope** Trial scope: Specify scope Other N/A

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Study design: Allocation	Study design: Masking	
Randomized controlled trial	Blinded (masking used)	
Study design: Control	Study phase	
Placebo	1	
Study design: Purpose	Study design: Specify purpose	
Treatment	N/A	
	Study design: Specify assignment	
Study design: Assignment	Study design: Specify assignment	
Study design: Assignment Parallel	Study design: Specify assignment N/A	
Parallel	N/A	
Parallel IMP has market authorization	N/A	
Parallel IMP has market authorization No	N/A IMP has market authorization: Specify	

Type of IMP

Others

Pharmaceutical class

Crovalimab is a novel, humanized anti-complement component 5 (C5) monoclonal antibody. Crovalimab binds to C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9 (membrane attack complex [MAC]). Crovalimab is based on Sequential Monoclonal Antibody Recycling Technology (SMART-Ig) (Recycling Antibody) (Fukuzawa et al. 2017) with pH-dependent antigen binding allowing for efficient target disposal, and enhancement of neonatal fragment crystallizable receptor binding to improve antibody recycling efficiency. These characteristics result in a prolonged half-life and prolonged complement inhibition. The physicochemical properties of crovalimab support the development of a high concentration formulation. The combination of the SMART-Ig and the highly concentrated formulation will enable up to every 4 weeks (Q4W) subcutaneous (SC) dosing. Based on clinical data from patients with paroxysmal nocturnal hemoglobinuria (PNH), nonclinical pharmacology and pharmacodynamic (PD) data, crovalimab is expected to achieve consistent C5 inhibition throughout the dosing interval.

Therapeutic indication

Study indication: Crovalimab is under development for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD) (Therapeutic indication for the submitted study BO42452)

Therapeutic benefit

 \sim

REPUBLIC OF LEBANON

Lebanon Clinical Trials Registry

Multiple studies have demonstrated markers of alternative pathway and terminal complement pathway activation in patients with SCD (Chudwin et al. 1994; Mold et al. 1995; Wang et al. 2011; Gavriilaki et al. 2019; Roumenina et al. 2020). Complement activation has been described in patients with SCD at baseline (Roumenina et al. 2020), in acute pain crisis (Mold et al. 1995), and in those with DHTR (Roumenina et al. 2019). Mechanisms for complement activation in patients with SCD may be multifactorial. A recent study found that the complement activation in SCD may be occurring on endothelial cells as a result of free heme activation of toll-like receptor 4,

leading to increased P-selectin expression, which anchors activated C3 fragments C3b and C3(H2O), triggering alternative pathway activity on endothelial cells (Merle et al. 2019). This suggests a mechanism for complement activation in the chronic

steady state in SCD from products of chronic hemolysis. This mechanism is supported by in vitro studies in whole blood of healthy volunteers, which have shown dose-response activation of terminal complement triggered by increasing amounts of

free heme (Thomas et al. 2019). Other studies have shown complement pathway activation through the alternative pathway from membrane phospholipid changes occurring in HbSS RBCs (Wang et al. 1993; Chudwin et al. 1994). Further, sickled RBCs have been shown to have increased susceptibility compared with normal erythrocytes to lysis by the terminal complement complex (Test and Woolworth 1994), suggesting a possible amplification loop in which hemolysis products activate complement, which promotes further destruction of sickled RBCs. Lastly, a link between complement activation and the dense, dehydrated cells that play a role in the pathophysiology of SCD has been demonstrated in whole blood of patients with SCD. Blood levels of soluble complement 5b 9 (sC5b-9), a marker of terminal complement pathway activation, were positively correlated with the percentage of dense sickle cells (Roumenina et al. 2020). In addition, expression of complement regulators on dense sickle cells is reduced (Roumenina et al. 2020). This could make these cells more susceptible to complement -mediated lysis.

Study model

N/A

Study model: Explain model

N/A

N/A

Study model: Specify model

N/A

Time perspective

N/A

Time perspective: Specify perspective N/A

Target follow-up duration: Unit

Time perspective: Explain time perspective

Number of groups/cohorts

Target follow-up duration

Biospecimen retention

Samples with DNA**

Biospecimen description

Samples for laboratory assessments for hematology (including reticulocytes), chemistry (including LDH), pharmacokinetics, ADA, pharmacodynamics and biomarkers will be taken as per schedule of assessment in the protocol Local Laboratory Assessments Samples for the following laboratory tests will be sent to the study site's local laboratory for analysis:

- Hematology: RBC count, hemoglobin, hematocrit, platelet count, WBC count, and

differential count (neutrophils, eosinophils, basophils, monocytes, lymphocytes,

other cells), and reticulocytes - Chemistry panel (serum or plasma): sodium, potassium,

chloride, bicarbonate, or total carbon dioxide (if considered SOC for the region), glucose,



Lebanon Clinical Trials Registry



REPUBLIC OF LEBANON

MINISTRY OF PUBLIC HEALTH

BUN or urea.

creatinine, magnesium, total and direct bilirubin, alkaline phosphatase, ALT, AST, $% \left({{\rm{AST}}} \right)$

and LDH

- Patients living in and/or traveling to/from a malaria endemic area within

1 month prior to enrollment will have a malaria microscopy or malaria RDT

performed per local guidelines (on Day 1 prior to randomization) - Pregnancy test: All women of childbearing potential will have a pregnancy test at

screening (serum or urine). Additionally at the end of the study, a urine pregnancy

test will be performed by the patient at home no more than 2 days before the

Day 322 telephone call. The patient should report the result of the pregnancy test

during the telephone call. At sites in France, the urine pregnancy test at the end of

the study will be performed at the Day 322 site visit. If a urine pregnancy test is

positive, it must be confirmed by a serum pregnancy test.

Hematology and chemistry labs that are not mandatory per protocol during

hospitalization, but are conducted as routine assessments according to local clinical practice, should be documented on the eCRF.

Central Laboratory Assessments

The following samples will be sent to one or several central laboratories, to the Sponsor,

or to a designee for analysis:

- Serum PK samples

- Serum ADA samples

- Plasma and serum samples for PD biomarkers (including total CH50 measurement

by LIA, total and free complement C5 concentration, and sC5-b9 concentration)

- Plasma and serum samples for exploratory biomarkers

- Urine samples for exploratory biomarkers

- Blood sample for clinical genotyping

Exploratory biomarker research may include, but will not be limited to markers of

hemolysis, immune cell activation, inflammation,

endothelial/vascular damage, and

end-organ (e.g., kidney) injury.

The PK, PD, ADA, and exploratory biomarker assessments will be conducted as

described in Appendix 1 and Appendix 2 during the hospitalization period, and

Appendix 3 during the observational period. Whenever possible, PK, PD and ADA

samples should be collected at the same time. Steady state SCD exploratory biomarker

samples (plasma/serum and urine) at Screen Visit #1 (initial screen) should only be

collected if this visit is conducted at an outpatient visit prior to VOE presentation, and

only after the main ICF is signed; it should otherwise be skipped. All pre-dose baseline

samples at VOE presentation must only be collected after the patient has been enrolled

on the study and must be within 24 hours before study treatment administration. Day 28

and Day 84 PK, PD, ADA, and biomarker samples will be collected at study site visits

during the observational period. However, if the patient continues to be hospitalized at

Day 28 and/or Day 84 for any reason, these samples should be collected in the hospital $% \left({\left| {{{\rm{D}}_{\rm{A}}} \right|} \right)$

on these days.

Lebanon Clinical Trials Registry

screening, it can be collected at any other

genome sequencing (WGS)

with the objective to

at screening

A mandatory blood sample for clinical genotyping will be collected

(see Appendix 1 of the protocol) or if the sample is missed at

data may be generated from the DNA obtained from blood, but

analyze C5 polymorphisms and other complement or SCD-related

timepoint during hospitalization or after discharge. Whole



MINISTRY OF PUBLIC HEALTH

Target sample size 30

Date of first enrollment: Type Actual

Date of study closure: Type Actual

Recruitment status Recruiting

Date of completion

IPD sharing statement plan

Yes

gene polymorphisms. Only one clinical genotyping sample is required per patient. If the patient gives consent, the remainder of the clinical genotyping samples (blood) and their derivatives (DNA) will be stored under the Research Biosample Repository (RBR) policy, otherwise the remainder will be destroyed. For sampling procedures, storage conditions, and shipment instructions, see the laboratory manual. Unless the patient gives specific consent for his or her leftover samples to be stored for optional exploratory research (see Section 4.5.14), biological samples will be destroyed no later than 5 years after the final Clinical Study Report has been completed. When a patient withdraws from the study, samples collected prior to the date of withdrawal may still be analyzed, unless the patient specifically requests that the samples be destroyed, or local laws require destruction of the samples. However, if samples have been tested prior to withdrawal, results from those tests will remain as part of the overall research data. Data arising from sample analysis, including data on genomic variants, will be subject to the confidentiality standards described in Section 8.4 of the protocol Given the complexity and exploratory nature of exploratory biomarker analyses, data derived from these analyses will generally not be provided to study investigators or patients unless required by law. The aggregate results of any conducted research will be available in accordance with the effective Sponsor policy on study data publication. Actual enrollment target size Date of first enrollment: Date 26/03/2022 Date of study closure: Date 30/04/2025 **Recruitment status: Specify**

IPD sharing statement description

REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry



The Sponsor maintains confidentiality standards by coding each
patient enrolled in the
study through assignment of a unique patient identification number. This means that
patient names are not included in datasets that are transmitted to
any Sponsor location.
Patient medical information obtained by this study is confidential
and may be disclosed
to third parties only as permitted by the ICF (or separate
authorization for use and disclosure of personal health information) signed by the patient,
unless permitted or
required by law.
Medical information may be given to a patient's personal
physician or other appropriate
medical personnel responsible for the patient's welfare, for
treatment purposes.
Given the complexity and exploratory nature of exploratory
biomarker analyses, data
derived from these analyses will generally not be provided to
study investigators or patients unless required by law. The aggregate results of any
conducted research will
be available in accordance with the effective Sponsor policy on
study data publication.
Data generated by this study must be available for inspection
upon request by
representatives of national and local health authorities, Sponsor monitors.
representatives, and collaborators, and the IRB/EC for each study
site, as appropriate.
Study data, which may include data on genomic variants, may be
submitted to
government or other health research databases or shared with researchers, government
agencies, companies, or other groups that are not participating in
this study. These data
may be combined with or linked to other data and used for
research purposes, to
advance science and public health, or for analysis, development, and commercialization
of products to treat and diagnose disease. In addition, redacted
Clinical Study Reports

Additional data URL

Admin comments

Trial status

Approved

Secondary Identifying Numbers		
Full name of issuing authority	Secondary identifying number	
EU CT NUMBER	2022-502546-26-00	





Sources of Monetary or Material Support

Name

F. HOFFMANN-LA ROCHE LTD

Secondary Sponsors

No Sponsors

Contac	Contact for Public/Scientific Queries					
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Adlette Inati	Tripoli, El Maarad street - Tripoli Lebanon	Lebanon	+961 3228033	adletteinati@outl ook.com	Hematolog ist at NINI Hospital
Scientific	Adlette Inati	Tripoli, El Maarad street - Tripoli Lebanon	Lebanon	+961 3228033	adletteinati@outl ook.com	Hematolog ist at NINI Hospital
Public	Ali Taher	AUBMC - Cairo STreet - Beirut Lebanon	Lebanon	00961-1- 350000	ataher@aub.edu. lb	Oncologist - Hematolog ist at AUBMC
Scientific	Ali Taher	AUBMC - Cairo STreet - Beirut Lebanon	Lebanon	00961-1- 350000	ataher@aub.edu. lb	Oncologist - Hematolog ist at AUBMC

Centers/Hospitals Involved in the Study			
Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
NINI HOSPITAL	Adlette Inati	Hematologist	Approved
AUBMC	Ali Taher	Hematologist - Oncologist	Approved

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
American University of Beirut Medical Center	20/02/2024	AUB IRB	irb@aub.edu.lb	T +961 1 35 00 00 – Ext 5445
Nini Hospital	25/03/2024	Dr Elias Bitar	NA	06431400





	-		
Count	rige of	Recruitmen	
Gound		Neoluittiett	

Name
Brazil
France
Italy
South Africa
Spain
Netherlands
United Kingdom
United States of America
Lebanon
Kenya

Health Conditions or Problems Studied		
Condition Code Keyword		Keyword
Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)	Sickle-cell disorders (D57)	sickle cell disease

Interventions		
Intervention	Description	Keyword
Crovalimab	Crovalimab will be supplied by the Sponsor as a solution for infusion (IV) from a single-use vial, which contains an extractable volume of 2 mL or 340 mg (nominal) crovalimab. For IV infusion, the crovalimab-vial solution should be diluted in 0.9% (w/v) sodium chloride solution prior to administration.	Crovalimab
Placebo	The placebo will be an aqueous, isotonic, and sterile solution with a similar pH value as the crovalimab drug product. It should be handled, stored, and used in the same manner as crovalimab. The placebo will be filled into the same primary container as the crovalimab drug product and will be administered by IV infusion with the same volume as weight-based crovalimab	Placebo



Lebanon Clinical Trials Registry

Primary Outcomes		
Name	Time Points	Measure
The safety objective for this study is to evaluate the safety of crovalimab compared with placebo	end of study	Incidence and severity of adverse events, with severity determined according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0) □ Change from baseline in targeted vital signs and clinical laboratory test results □ Incidence and severity of infusion-related reactions and hypersensitivity
The PK objective for this study is to characterize the crovalimab PK profile	end of study	Serum concentrations of crovalimab over time Relationships between drug exposure and pharmacodynamics, efficacy or safety endpoints of crovalimab (patients randomized to crovalimab)
The PD objective for this study is to evaluate PD biomarkers that can provide evidence of crovalimab activity	end of study	Change over time in PD biomarkers, including total complement activity (CH50) measured by a LIA, total and free complement component 5 (C5) concentration, and sC5b-9 concentration
The efficacy objective for this study is to characterize the efficacy of crovalimab compared with placebo	end of study	□ Time to improvement of the primary acute uncomplicated VOE (for definition, see Section 2.4.1) from baseline, defined as the first achieved from the following criteria: – Confirmed decrease in pain score of at least 2 points from the maximal pre-dose pain score, that is sustained in at least two pain assessments conducted a minimum of 6 hours apart from each other (as measured with the Numerical Rating Scale [NRS] on a 0 □ 10 scale) AND transition to oral pain medications for a minimum of 6 hours after the completion of the last dose of parenteral opioids, OR – Readiness for hospital discharge (as defined by the patient's assessment that pain can be managed at home AND agreement from investigator), OR – Hospital discharge □ Total cumulative opioid dose (parenteral and oral) in morphine equivalents per kilogram units (MEU/kg) from baseline to the time of acute uncomplicated VOE improvement □ Time to discontinuation of all parenteral opioids from baseline (defined as time from baseline to the completion of the last dose of parenteral opioids) □ Time to readiness for hospital discharge from baseline □ Time to hospital discharge from baseline □ Time to a confirmed decrease in pain score of at least 2 points from the maximal pre-dose pain score, that is sustained in at least two assessments conducted a minimum of 6 hours apart from each other, as measured with the NRS on a 0 □ 10 scale Change in pain score from the maximal pre-dose pain score to the score at hospital discharge, as measured with the NRS on a 0 □ 10 scale □ Proportion of patients who develop ACS from baseline to Day 28 □ Proportion of patients requiring intensive care unit (ICU)/critical care admission for SCD-related complications from baseline to the time of hospital discharge □ Proportion of patients requiring blood transfusion for SCD-related complications from baseline to the time of hospital discharge □ Readmission rate for a VOE or VOE-related event within 28 days of discharge of the primary acute uncomplicated VOE



Key Secondary Outcomes		
Name	Time Points	Measure
The immunogenicity objective for this study is to evaluate the immune response to crovalimab	End of study	Prevalence of anti-drug antibodies (ADAs) at baseline and incidence of ADAs during the study (patients randomized to crovalimab) □ Potential effects of ADAs on efficacy, safety, or PK endpoints
The exploratory biomarker objective for this study is to identify and/or evaluate biomarkers that are predictive of response to crovalimab (i.e., predictive biomarkers), are early surrogates of efficacy, are associated with progression to a more severe disease state (i.e., prognostic biomarkers), are associated with resistance to crovalimab, are associated with susceptibility to developing adverse events or can lead to improved adverse event monitoring or investigation (i.e., safety biomarkers), or can increase the knowledge and understanding of disease biology and drug safety,	End of study	Observed value and change over time in exploratory biomarkers including but not limited to markers of hemolysis, immune cell activation, inflammation, endothelial/vascular damage, and end- organ injury Relationship between biomarkers in blood and efficacy, safety, pharmacokinetics, immunogenicity, or other biomarker endpoints

Trial Results

Summary results	
Study results globally	
Date of posting of results summaries	Date of first journal publication of results
Results URL link	
Baseline characteristics	
Participant flow	
Adverse events	
Outcome measures	
URL to protocol files	